Characristics | Hazard ratio | 95% CI | P-value |
---|---|---|---|
Univariate analysis | |||
Gender (male vs. female) | 0.422 | 0.232-0.770 | 0.005* |
Age (< 46 vs. ≥ 46) | 1.721 | 1.085-2.729 | 0.021* |
WHO type (I vs. IV) | 1.025 | 0.618-1.700 | 0.925 |
Clinical stage (I + II vs. III + IV) | 1.824 | 1.012-3.286 | 0.045* |
T stage (T1~2 vs. T3~4) | 1.571 | 0.972-2.540 | 0.065 |
N stage (N0 vs. N1~3) | 0.936 | 0.568-1.544 | 0.796 |
Recurrence (no vs. yes) | 1.442 | 0.895-2.322 | 0.132 |
Metastasis (no vs. yes) | 2.466 | 1.412-4.304 | 0.002* |
LMP1 expression (low vs. high) | 1.863 | 1.091-3.183 | 0.023* |
p-mTOR expression (low vs. high) | 1.274 | 0.796-2.040 | 0.314 |
p-P70S6K expression (low vs. high) | 1.447 | 0.907-2.309 | 0.121 |
p-4EBP1 expression (low vs. high) | 1.920 | 1.154-3.195 | 0.012* |
Multivariate analysis | |||
Gender (male vs. female) | 0.447 | 0.234-0.851 | 0.014* |
Metastasis (no vs. yes) | 2.591 | 1.383-4.856 | 0.003* |
LMP1 expression (low vs. high) | 2.056 | 1.161-3.641 | 0.013* |